HSP90 Monoclonal antibody, PBS Only

HSP90 Monoclonal Antibody for WB, IP, IF, IHC, ELISA

Host / Isotype

Mouse / IgG2a

Reactivity

human, mouse, rat, pig

Applications

WB, IP, IF, IHC, ELISA

Conjugate

Unconjugated

CloneNo.

3F11C1

Cat No : 60318-1-PBS

Print datasheet

Synonyms

FLJ31884, Heat shock 86 kDa, HSP 86, HSP86, Hsp89, HSP89A, HSP90, HSP90A, HSP90AA1, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, LAP2



Planning an IHC experiment? We recommend our IHCeasy HSP90AA1 Ready-To-Use IHC Kit. HSP90AA1 primary antibody included.

产品信息

60318-1-PBS targets HSP90 in WB, IP, IF, IHC, ELISA applications and shows reactivity with human, mouse, rat, pig samples.

Tested Applications WB, IP, IF, IHC, ELISA Application Description
Tested Reactivity human, mouse, rat, pig
Immunogen HSP90 fusion protein Ag3826 种属同源性预测
Host / Isotype Mouse / IgG2a
Class Monoclonal
Type Antibody
Full Name heat shock protein 90kDa alpha (cytosolic), class A member 1
Synonyms FLJ31884, Heat shock 86 kDa, HSP 86, HSP86, Hsp89, HSP89A, HSP90, HSP90A, HSP90AA1, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, LAP2
Calculated Molecular Weight 853 aa, 90 kDa
Observed Molecular Weight 85-90 kDa
GenBank Accession NumberBC023006
Gene Symbol HSP90AA1
Gene ID (NCBI) 3320
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
UNIPROT IDP07900
Storage Buffer PBS only
Storage ConditionsStore at -80°C.

背景介绍

HSP90, encoded by HSP90AA1, is a constitutively and ubiquitously expressed molecular chaperone that is crucial for the stability and function of many proteins. HSP90 provides chaperoning activity for client proteins; many of them are members of oncogenic pathways, indicating its implication in tumor malignancy. HSP90 mainly resides in the cytosol, while it can also be released to the extracellular space. Secreted Hsp90 is a C-terminal truncated form. It has been reported that the level of plasma Hsp90 is positively correlated with tumor malignancy in clinical cancer patients, and can be a promising diagnostic marker for tumor malignancy in clinical application.